{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:24:54Z","timestamp":1783085094343,"version":"3.54.6"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jns.2023.120689","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T06:38:18Z","timestamp":1684132698000},"page":"120689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Natalizumab extended-interval dosing in a real-life setting"],"prefix":"10.1016","volume":"450","author":[{"given":"Lina","family":"Jeantin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Gueguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustin","family":"Lecler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2023.120689_bb0005","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.jns.2023.120689_bb0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2023.120689_bb0015","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","author":"Ryerson","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2023.120689_bb0020","series-title":"MS Disease Activity in Restore","volume":"11","author":"Fox","year":"2014"},{"issue":"7","key":"10.1016\/j.jns.2023.120689_bb0025","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2023.120689_bb0030","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3174\/ajnr.A5690","article-title":"Improved detection of new MS lesions during follow-up using an automated MR coregistration-fusion method","volume":"39","author":"Galletto Pregliasco","year":"2018","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"3","key":"10.1016\/j.jns.2023.120689_bb0035","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/nmt-2021-0038","article-title":"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis","volume":"12","author":"Moccia","year":"2022","journal-title":"Neurodegener. Dis. Manag."},{"issue":"6","key":"10.1016\/j.jns.2023.120689_bb0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2023.120689_bb0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Multiple Sclerosis Relat. Disord."},{"issue":"8","key":"10.1016\/j.jns.2023.120689_bb0050","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2023.120689_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.716548","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses","volume":"12","author":"Serra L\u00f3pez-Matencio","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2023.120689_bb0060","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.jns.2023.120689_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-330467","article-title":"Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis","volume":"94","author":"Toorop","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2023.120689_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117622","article-title":"Wearing-off symptoms during standard and extended natalizumab dosing intervals: experiences from the COVID-19 pandemic","volume":"429","author":"Bringeland","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2023.120689_bb0075","article-title":"Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic","author":"Magro","year":"2022","journal-title":"J. Neurol. [Internet]"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:01:28Z","timestamp":1758384088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X23001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"alternative-id":["S0022510X23001491"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.120689","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natalizumab extended-interval dosing in a real-life setting","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.120689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120689"}}